Home / Markets / Industries / Health Care
Friday, November 07, 2008
Medtronic Announces Key Activities at American Heart Association Scientific Sessions 2008
Comtex
MINNEAPOLIS, Nov 07, 2008 (BUSINESS WIRE) ----Consistent with its long-standing commitment to clinical excellence in advanced cardiac care, Medtronic, Inc. (NYSE: MDT) today announced key activities during Scientific Sessions 2008, at the annual congress of the American Heart Association, being held Nov. 8-12, 2008 at the Morial Convention Center in New Orleans. Of note, evidence further demonstrating the clinical benefit of painless anti-tachycardia pacing (ATP) will be presented. Additionally, the first U.S. clinical trial data on the Melody(R) transcatheter pulmonic heart valve will be presented, representing the first time U.S. clinical trial data has been presented on the use of a transcatheter valve in a population with congenital heart disease. Both sessions will be held Monday, Nov. 10:
-- Differences in Effects of Electrical Therapy for Ventricular Arrhythmias on Mortality in ICD patients, from 9:15-9:30 a.m. in Room 243-245, presented by Michael O. Sweeney, M.D., Brigham and Women's Hospital, Boston.
-- Implantation of the Medtronic Melody Transcatheter Pulmonary Valve in Patients with Dysfunctional Right Ventricular Outflow (RVOT) Conduits: Procedural and 6-Month Results from U.S. Feasibility Trial, from 2-2:15 p.m. in Room 220-222, presented by Doff B. McElhinney, M.D., Children's Hospital, Boston.
Clinical data from studies sponsored or supported by Medtronic will be featured in more than 30 presentations during Scientific Sessions 2008. Additionally, congress attendees are encouraged to visit Medtronic's main booth no. 401, where the following presentations will be held:
Sunday, Nov. 9
-- Controversies in the Identification, Assessment and Treatment of Heart Failure: Findings from the IMPROVE HF Study, from 11:30 a.m.-noon featuring Gregg Fonarow, M.D., UCLA Medical Center
-- Product Innovation and Quality: How to Balance Risk Versus Benefit, from 12:45-1:15 p.m. featuring Larry Rosenthal, M.D., UMass Memorial Medical Center
Monday, Nov. 10
-- Cardiac Resynchronization Therapy is a Class I Indication: Why Are Only 1/3 Being Treated?, from 11:30 a.m.-noon featuring William T. Abraham, M.D., The Ohio State University
-- New Evidence that Reducing Shocks May Prolong Survival in ICD Patients, from 12:15-12:45 p.m. featuring Michael O. Sweeney, M.D., Brigham and Women's Hospital
-- Managing HF Patients Based on OptiVol(R) and CareAlerts(TM), from 1-1:30 p.m. featuring Carsten Stoepel, M.D., Lukas Hospital Neuss
Attendees will have the opportunity to learn more about the improved Medtronic CareLink(R) Network, Vision 3D(TM) portfolio of products, CardioSight(R) Service, and many of the leading products Medtronic has developed for physicians to deliver better care to their patients. Innovations from Medtronic CardioVascular's international product portfolio on display will include:
-- Driver(R) and Micro-Driver(R) bare-metal stents
-- Endeavor(R) and Endeavor Resolute(TM) drug-eluting stents
-- Sprinter(R) Legend(TM) angioplasty balloon catheter
-- Export(R) thrombus aspiration catheter
-- Interceptor(R) coronary filter system
-- Talent(TM) Stent Grafts for aortic aneurysm repair
-- Melody(R) transcatheter pulmonic heart valve
Visitors also are encouraged to stop by the Medtronic Mobile Therapy and Procedure Training Center at booth no. 119 to practice lead placement and simulate coronary interventional procedures inside the firm's Virtual Cath Lab(R) and explore real human and animal hearts in various disease stages, as provided by the Medtronic-supported Visible Heart(R) Lab.
About Medtronic
Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology -- alleviating pain, restoring health, and extending life for millions of people around the world.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.
SOURCE: Medtronic, Inc.
Medtronic, Inc. Public Relations, CRDM: Kyra Schmitt, 763-526-2490 or Public Relations, CV: Joe McGrath, 707-591-7367 or Investor Relations: Jeff Warren, 763-505-2696
Copyright Business Wire 2008 ********************************************************************** As of Monday, 11-03-2008 23:59, the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated a DOWNTREND on 09-17-2008 for MDT @ $52.47. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright � 2004-2008 Comtex News Network, Inc. All rights reserved.
FOX Translator
No data currently available.
No data currently available.
Some mutual funds want you to pay for the privilege of them (or your investment adviser) taking your money to invest. It's called a load, and it works like a cover charge to get into a nightclub. Luckily, there are such things as no-load funds. As the name implies, shares of these funds are sold without a fee paid to a broker or investment advisor.
The entire amount you invest in no-load funds goes to work for your returns. On the other hand, with load funds, right off the bat you're charged commission (not to mention other fees incurred over the life of the investment). Let's say, for example, you invest $25,000 into a load fund that charges a 5% commission. This costs you $1,250 off the top, bringing your actual investment down to only $23,750.
The often-cited horse race analogy argues against investing in load funds. Here's the logic behind it: Would you place a bet on a horse that had to start a race 200 yards behind the others? Well, maybe you would if you got a tip from a sketchy, trench coat-clad man in a dark alley. However, under most circumstances, it's not smart to put your money on that handicapped horse.
But some argue that at times that man in the trench coat (aka your broker) knows more about the horses than you do, and has a better shot at picking a winner. Also, sometimes these fees are unavoidable because some funds are available only through investment advisers.
Cost-benefit analysis can help determine when a load fund is worth it (in other words, when it will score you a load) and when it is better to "do it yourself" and avoid the fees. Load-fund fees range depending on share class and can cover a variety of costs, such as paper work and fund management.
